Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bladder-preservation multimodality trial in high-risk invasive bladder cancer
NL-OMON43780Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, methotrexate, vinblastine, doxorubicin, gemcitabine and 3 more in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by Netherlands Cancer Institute. Primary endpoints: Bladder-preservation rate after chemoradiation and Recurrence of disease after 12 months follow-up following chemoradiation. Started Sep 2015; status: active, not recruiting.
02
Drugs
cisplatinmethotrexatevinblastinedoxorubicingemcitabine
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NL-OMON43780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43780.